What is Microbix Biosystems?
Founded in 1988 and headquartered in Mississauga, Ontario, Canada, Microbix Biosystems is a publicly-traded entity on the TSX and OTCQB. The company specializes in developing proprietary biological and technology solutions aimed at enhancing human health and well-being. Microbix is a key supplier of essential biological materials for the global diagnostics industry, providing antigens for immunoassays and laboratory quality assessment products (QAPs) that are crucial for clinical lab proficiency testing, assay development, and ensuring the quality of clinical diagnostic workflows. Beyond diagnostics, Microbix leverages its biological expertise to develop unique products, including Kinlytic® urokinase, a biologic thrombolytic drug designed for the treatment of blood clots.
How much funding has Microbix Biosystems raised?
Microbix Biosystems has raised a total of $2.3M across 1 funding round:
Share Placement
$2.3M
Share Placement (2020): $2.3M, investors not publicly disclosed
What's next for Microbix Biosystems?
The recent major strategic investment signals a pivotal phase for Microbix Biosystems, likely enabling the company to accelerate its product development pipelines, expand its manufacturing capabilities, and broaden its market reach. This capital infusion is expected to bolster its efforts in both the diagnostics and therapeutics sectors, particularly in advancing its Kinlytic® urokinase drug and enhancing its portfolio of biological materials for the diagnostics industry. The company's strategic focus will likely involve further solidifying its market leadership and exploring new applications for its proprietary technologies.
See full Microbix Biosystems company page
